Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2018

View Archived Issues

Arrevus receives NIAID grant to support research using ARV-1502

Japanese authorities grant Sakigake designation to CLBS-12

Sakigake designation awarded to tafamidis meglumine

Novel HBsAg secretion inhibitors synthesized at Novartis

NOTCH and MAPK signaling linked to worse colorectal cancer survival

Preliminary phase I pharmacokinetic data reported for AZD-8186

Mylan to introduce new triple combo once-daily HIV treatment in U.S.

Incyte patents novel MAP4K1 inhibitors

Nabriva Therapeutics and Roivant Sciences enter lefamulin license agreement

New mu-opioid receptor agonists identified at Mebias Discovery

GlaxoSmithKline presents novel viral 3C and 3CL protease inhibitors

The University of Saskatchewan divulges alpha-synuclein aggregation inhibitors

FDA grants orphan drug designation to CYP-001

Edge Therapeutics discontinues phase III NEWTON 2 study of EG-1962

First patient enrolled in phase IIb trial of AmnioFix Injectable for the treatment of OA of the knee

Vifor Pharma grants Zeria license to develop and market Veltassa in Japan

Abide Therapeutics grants Celgene worldwide license for ABX-1772

EMA accepts BioMarin's MAA for pegvaliase to treat adults with PKU

Lanadelumab submissions in E.U. and Canada accepted for review

Urovant initiates phase III trial of vibegron in overactive bladder

Balixafortide/eribulin combination shows antitumor activity in metastatic breast cancer patients

Curadim licenses rights to Ube's LPA1 selective antagonist

MediciNova announces plans to study MN-166 for chemotherapy-induced peripheral neuropathy

pSivida announces acquisition of Icon Bioscience

Kazia Therapeutics initiates phase II trial of GDC-0084

Five Prime initiates phase I study of first-in-class B7-H4 antibody FPA-150

METTL3 linked to hepatocellular carcinogenesis

Prometic Life Sciences offers new data from phase II study of PBI-4050 in Alstrom syndrome

Janssen files for approval of apalutamide in Japan

Takeda considers making offer for Shire

Zeria Pharmaceutical applies for approval of Z-213 in Japan

Redx suspends enrollment in phase I/IIa study of RXC-004

C4X licenses orexin-1 receptor antagonist C4X-3256 to Indivior

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.